About this medicine
Product information is provided to support understanding and conversations with your care team. Follow the approved leaflet and your prescriber’s instructions.
Content migrated from the company website; pending clinical review before final publication.
Dosage forms
Oral capsules (150 and 200 mg)
Drug class
Tyrosine kinase inhibitor
Administration
Take twice daily, 12 hours apart, preferably on an empty stomach (at least one hour before or two hours after food).
Uses
• Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML), resistant to previous treatment
• Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), resistant or recurrent
• Treatment-resistant gastrointestinal stromal tumor (GIST)
Competitive advantages
As a tyrosine kinase inhibitor with greater effectiveness than imatinib, nilotinib has provided outstanding clinical outcomes, particularly in patients resistant to previous treatment. Through more precise inhibition of the BCR-ABL pathway, nilotinib not only slows disease progression but also minimizes the risk of drug resistance.
Its high effectiveness and better safety profile than other tyrosine kinase inhibitors make nilotinib a suitable choice for patients with CML.
Original company product page ↗